Mohamad Al Sayed, MD
Endocrinology, Diabetes & Metabolism · Riverside, CANPI 1568428134
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,266, 3.2 times the $700 reported in 2019.
Across 188 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$720
- Amgen$584
- Novo Nordisk$536
- Medtronic$398
- Dexcom, Inc.$297
- Verity Pharmaceuticals Inc.$254
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,52799%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $720 |
| Amgen(2 entities) | 25 | $584 |
| Novo Nordisk | 29 | $536 |
| Medtronic(2 entities) | 16 | $398 |
| Dexcom, Inc. | 7 | $297 |
| Verity Pharmaceuticals Inc. | 1 | $254 |
| Corcept Therapeutics | 5 | $189 |
| Sanofi-aventis U.S. LLC | 8 | $160 |
| Recordati_rare_diseases_inc. | 5 | $146 |
| Insulet Corporation | 5 | $135 |
| Mannkind Corporation | 8 | $124 |
| AbbVie | 4 | $100 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Radius Health, Inc. | 3 | $80 |
| Bayer | 3 | $75 |
| Madrigal Pharmaceuticals | 3 | $75 |
| Abbott | 3 | $72 |
| Boehringer Ingelheim | 5 | $67 |
| Neurocrine Biosciences, Inc. | 2 | $63 |
| Merck | 4 | $55 |
| Ascendis Pharma Endocrinology Inc | 2 | $51 |
| Tandem Diabetes Care, Inc. | 3 | $49 |
| Novartis | 2 | $45 |
| AstraZeneca | 3 | $39 |
| Grifols USA, LLC | 1 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Boston Scientific | 1 | $26 |
| Embecta Corp. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| United Therapeutics Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TLANDO$254
- TEPEZZA$150
- MOUNJARO$125
- Korlym$115
- DEXCOM G6 TRANSMITTER$108
How this compares
$4,572 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $95,471 |
| TrulicityDulaglutide | 65 | $68,037 |
| JardianceEmpagliflozin | 48 | $55,029 |
| MounjaroTirzepatide | 30 | $40,769 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $11,926 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,080 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $2,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,948 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $1,323 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 11 | $1,069 |
| Easy Comfort Pen NeedlesPen Needle, Diabetic | 11 | $981 |
| Levothyroxine Sodium | 75 | $711 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $630 |
| Glipizide ErGlipizide | 37 | $583 |
| Atorvastatin Calcium | 63 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $720 | $108,80695 claims |
| Novo NordiskOzempic | $536 | $95,47183 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $67 | $66,95563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Riverside
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.